O
Ophelia
Medication and support for opioid withdrawal, in the privacy of home
About Ophelia
Ophelia is a healthcare startup focused on providing medication-assisted treatment (MAT) for individuals struggling with opioid dependence. The company operates in the healthcare sector, specifically targeting patients who are experiencing cravings or withdrawal symptoms related to opioid use. Ophelia's business model revolves around offering scientifically-backed treatments that replace traditional rehab methods with a more modern, private, and convenient approach. The company makes money by providing these medical services directly to patients, leveraging a team of doctors, scientists, and tech experts to deliver high-quality care. Ophelia's mission is to eliminate the stigma associated with drug rehab by offering a discreet and effective alternative that empowers patients to make their own choices. The company serves a diverse clientele, primarily focusing on individuals under the age of 50, who are at the highest risk of opioid overdose. By combining medical expertise with a patient-centric approach, Ophelia aims to revolutionize the way opioid dependence is treated in the United States.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1994
- Headquarters
- New York City, United States
- Employees
- 374
- Open positions
- None listed
- Dealroom signal
- 86.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, YC W20
- Business model
- Marketplace & ecommerce
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2021 | $50M | $200M | Interplay · Refactor Capital · General Catalyst · Menlo Ventures | ↗ |
| SERIES AOther financing | Apr 2021 | $15M | $60M | Refactor Capital · Bloom Institute of Technology · Menlo Ventures · General Catalyst | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Ophelia is 580K monthly website visits, down 29.3% over the last three months. Ophelia's team grew 12.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
General Catalyst
Y Combinator
Refactor Capital
Series A10 investors entered at this stage
Menlo Ventures
Bloom Institute of Technology
Warby Parker
Harry's
PillPack
Smartbird | formerly Allbirds
Carbon Health
Tiger Global
Interplay- 6V640 Oxford Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ophelia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ophelia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.